In 2019, the global demand for late-stage chronic kidney disease therapeutics was estimated to be around US$ 4.7 billion. However, due to the rising prevalence of chronic kidney disease around the world, the global late stage kidney disease therapeutics market is expected to surpass US$ 11.1 billion in 2027 and grow at a robust CAGR of around 11.6% during the forecast period. (2022 to 2032)
Late-stage chronic kidney disease therapeutics can be defined as the drugs which are used for the treatment of late-stage CKD – Induced, Hyperphosphatemia, Hyperparathyroidism, and Hyperkalemia.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-9195
The dramatic increase in CKD prevalence have maintaining the unmet need for the late stage chronic kidney disease therapeutics. In spite of the introduction of new late stage chronic kidney disease therapeutics the market is expected to have opportunity to grow.
Late Stage Chronic Kidney Disease Therapeutics Market: Drivers and Restraints
The rise in the prevalence of CKD are the main reason for the increasing demand of late stage chronic kidney disease therapeutics. As per to CDC, 15% of the US adults are suffering from CKD and 48% of the CKD patients are not aware of the condition or not on dialysis.
On the other hand the introduction of new late stage chronic kidney disease therapeutics such as calcimimetic and new HK agents is expected to drive the growth of the late stage chronic kidney disease therapeutics market in the forecast period.
Favourable reimbursement policy for the late stage chronic kidney disease therapeutics and rising awareness among patients and practitioner for the consequences of CKD is also fuelling the market of late stage chronic kidney disease therapeutics.
In the saturated market of late stage chronic kidney disease therapeutics, the new entrants will face problem to establish their presence in the late stage chronic kidney disease therapeutics market. Although agreements and partnerships between dialysis centers and manufacturers will remain a key strategy to maintain dominance in late stage chronic kidney disease therapeutics market.
Unlock exclusive insights with our expert analysts:
https://www.futuremarketinsights.com/askus/rep-gb-9195
Late Stage Chronic Kidney Disease Therapeutics Market: Overview
Global late stage chronic kidney disease therapeutics market has witnessed growth due to rising prevalence of chronic kidney diseases. The introduction of new therapies and favorable reimbursement scenario for the late stage chronic kidney disease therapeutics also propel the growth of the market
Late Stage Chronic Kidney Disease Therapeutics Market: Region-wise Outlook
Geography wise, late stage chronic kidney disease therapeutics market is divided into seven regions viz. North America, Latin America, Europe, Middle East & Africa (MEA), South Asia, East Asia and Oceania. Favorable reimbursement and rising prevalence of CKD in the North American region is expected influence the market and therefore the North America late stage chronic kidney disease therapeutics market will remain dominant in the forecast period.
Late Stage Chronic Kidney Disease Therapeutics Market: Key Market Participants
Some of the market participants in the global late stage chronic kidney disease therapeutics market identified across the value chain include: AbbVie, Amgen, Ardelyx, AstraZeneca, Deltanoid, Genzyme, Keryx, Kyowa Hakko Kirin, Mitsubishi Tanabe, OPKO Health, Relypsa, Sanofi, Shield Therapeutics, Shire, Spectrum, Vifor and ZS Pharma
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.
The report covers exhaust analysis on:
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Technology
- Value Chain
Regional analysis includes:
- North America (U.S., Canada)
- Latin America (Mexico. Brazil)
- Europe (Germany, Italy, France, U.K., Spain, BENELUX, Russia, Rest of Europe)
- South Asia (India, Thailand, Indonesia, Malaysia, Rest of South Asia
- East Asia (China, Japan, South Korea)
- Oceania (Australia and New Zealand)
- Middle East and Africa (GCC Countries, S. Africa, Northern Africa, Turkey and Rest of MEA)
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Unlock Tailored Insights: Customize Your Report for Maximum Impact:
https://www.futuremarketinsights.com/customization-available/rep-gb-9195
Late Stage Chronic Kidney Disease Therapeutics Market: Segmentation
To gain a comprehensive and a better understanding of the future late stage chronic kidney disease therapeutics market equity, the market report is segmented based on product type, clinical practice, indication end user and region.
Based on the product type late stage chronic kidney disease therapeutics is segmented into:
- Calcimimetics
- Sensipar (cinacalcet hydrochloride)
- Vitamin D Sterols
- Nutritional/Native Vitamin D
- Vitamin D Receptor Agonists
- Phosphate Binders
- Calcium-Based Phosphate Binders
- Aluminum-Containing Phosphate Binders
- Magnesium-Containing Phosphate Binders
- Renvela/Renagel
- Fosrenol (lanthanum carbonate)
- Velphoro (sucroferric oxyhydroxide)
- Auryxia (ferric citrate)
- Potassium Binders
- Resins
- Veltassa (patiromer sorbitex calcium)
On the basis of indication, Late Stage Chronic Kidney Disease Therapeutics Market can be segmented as:
- Late Stage Chronic Kidney Disease Induced Hyperparathyroidism
- Late Stage Chronic Kidney Disease Induced Hyperphosphatemia
- Late Stage Chronic Kidney Disease Induced Hyperkalemia
On the basis of end users, late stage chronic kidney disease therapeutics market can be segmented as:
- Hospital Pharmacy
- Retail Pharmacy
- Mail Order Pharmacy
On the basis of geography, late stage chronic kidney disease therapeutics market can be segmented as:
- North America
- Latin America
- Europe
- Middle East & Africa (MEA)
- South Asia
- East Asia
- Oceania
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
